Clicky

Medicenna Therapeutics Corp.(MDNA)

Description: Medicenna Therapeutics Corp, formerly A2 Acquisition Corp, is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing engineered versions of Interleukin (IL)-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines (ECs). The Company focuses on commercialization EC and Superkines for the treatment of cancer. The Company's IL4 EC is a drug that targets the Bulk Tumor, Cancer Stem Cells and Immunosuppressive Cells of the Tumor Micro-environment. MDNA55 is the Company's lead product. MDNA55 is being studied in clinical trials for treatment of CNS cancers. The Company's MDNA56 and MDNA57 are its IL-4 carrying a human cell killing payload. MDNA56 is being developed for the treatment of hematopoietic cancers expressing the Type 1 IL-4R, whereas MDNA57 is intended to selectively target solid tumors and non-malignant cells of the tumor micro-environment expressing the Type 2 IL-4R.


Keywords: Cancer Clinical Medicine Solid Tumors Clinic Oncology Tumor Immunotherapy Treatment Of Cancer Clinical Trial Cancer Immunotherapy T Cell Cytokine Clusters Of Differentiation Interleukins Hematopoietic Cancers Interleukin 4

Home Page: www.medicenna.com

MDNA Technical Analysis

2 Bloor Street West
Toronto, ON M4W 3E2
Canada
Phone: 416 648 5555


Officers

Name Title
Dr. Fahar Merchant Ph.D. Founder, Chairman, Pres & CEO
Ms. Rosemina Merchant B.Sc., M.E.Sc Founder, Chief Devel. Officer & Director
Ms. Elizabeth Williams C.A., CPA, CA, CPA CFO & Corp. Sec.
Dr. Martin Bexon M.D., MBBS Acting Chief Medical Officer & Head of Clinical Devel.
Dr. Samuel R. Denmeade M.D. Scientific Advisor

Exchange: TO

Country: CA : Canada

Currency: Canadian Dollar (C$)

Forward PE: 204.0816
Trailing PE: 0
Price-to-Book MRQ: 1.3962
Price-to-Sales TTM: 0
IPO Date:
Fiscal Year End: March
Full Time Employees: 18
Back to stocks